Article Text

other Versions

PDF
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
  1. Marc Ferrante (marc.ferrante{at}uz.kuleuven.be)
  1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    1. Liesbet Henckaerts
    1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
      1. Marie Joossens
      1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
        1. Marie Pierik
        1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
          1. Sofie Joossens
          1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
            1. Nir Dotan
            1. Glycominds Ltd, Lod, Israel
              1. Gary Norman
              1. INOVA Diagnostics Inc, San Diego, CA, United States
                1. Rom Altstock
                1. Glycominds Ltd, Lod, Israel
                  1. Kristel Van Steen
                  1. Department of Applied Mathematics and Computer Science, University Gent, Belgium
                    1. Paul Rutgeerts
                    1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
                      1. Gert Van Assche
                      1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
                        1. Séverine Vermeire (severine.vermeire{at}uz.kuleuven.ac.be)
                        1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium

                          Abstract

                          Background and aims: Several antibodies have been associated with Crohn's disease (CD) and are associated with distinct clinical phenotypes. Our aim was to determine whether a panel of new antibodies against bacterial peptides and glycans could help in differentiating inflammatory bowel disease (IBD), and whether they were associated with particular clinical manifestations.

                          Methods: Antibodies against a mannan epitope of Saccharomyces cerevisiae (gASCA), laminaribioside (ALCA), chitobioside (ACCA), mannobioside (AMCA), outer membrane porins (Omp) and the atypical perinuclear antibody pANCA were tested in serum samples of 1225 IBD patients, 200 healthy controls (HC) and 113 patients with non-IBD gastrointestinal inflammation (non-IBD GI). Antibody responses were correlated with type of disease and clinical characteristics.

                          Results: 76% of CD patients had at least one of the tested antibodies. For differentiation between CD and ulcerative colitis (UC), the combination of gASCA and pANCA was most accurate. For differentiation between IBD, HC and non-IBD GI, the combination of gASCA, pANCA and ALCA had the best accuracy. Increasing amount and level of antibody responses towards gASCA, ALCA, ACCA, AMCA and Omp was associated with more complicated disease behaviour (44.7% vs. 53.6% vs. 71.1% vs. 82.0%, p < .001), and higher frequency of CD-related abdominal surgery (38.5% vs. 48.8% vs. 60.7% vs. 75.4%, p < .001).

                          Conclusions: Using this new panel of serological markers, we showed that number and magnitude of immune responses to different microbial antigens are associated with severity of the disease. To conclude on the predictive role of serological markers, prospective longitudinal studies are necessary.

                          • behavior
                          • differentiation
                          • glycan
                          • inflammatory bowel disease
                          • serological markers

                          Statistics from Altmetric.com

                          Request permissions

                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.